Compare Cytokinetics Inc (CYTK) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Kaltura Inc — how do they compare? Cytokinetics Inc trades at $76.66 (market cap $10.78B), while Kaltura Inc trades at $1.63 (market cap $250.18M). The key difference: Cytokinetics Inc is far larger — about 43.1× Kaltura Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | KLTR | |
|---|---|---|
Market Cap | $10.78B | $250.18M |
Sector | Technology | Technology |
52-Week High | $87.26 | $1.89 |
52-Week Low | $34.31 | $1.08 |
Enterprise Value | $10.88B | $262.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Kaltura (KLTR) trades at $1.75, up 1.74% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue is stable around $181M, but the company remains unprofitable with a net margin of -6.92%. Positive cash flow from operations and industry recognitions for AI and video platforms highlight growth potential, though high debt and insider selling pose concerns.
The outlook is mixed: analyst consensus leans buy (44% buy ratings) on AI innovation and cash flow improvements, but risks include persistent losses, elevated valuation ratios, and competitive pressures. Investors should weigh cost control progress against profitability challenges for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
